Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 4/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibenadet SCHEMBL30438496 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL249498 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Sibenadet SCHEMBL678828 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528403 | 0.93 | ABCB11 (0.93) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8527365 | 0.92 | ABCB11 (0.92) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL8528272 | 0.91 | ADRB2 (0.84) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL8533852 | 0.91 | ADRB2 (0.82) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL7829477 | 0.90 | ADRB2 (0.81) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| Hydrochloric Acid SCHEMBL7842790 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2PDE4AABCB11 | |
| SCHEMBL5386480 | 0.89 | ADRB2 (0.80) | ADRB2ADRB1DRD2PDE4AABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106390128-B | Use of beta-adrenergic inverse agonists for smoking cessation | 伊沃恩有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | claimed |
| US-20120010179-A1 | Methods of using a thiazole derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | claimed |
| EP-1617819-B1 | RADIOACTIVELY MARKED MICROPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME | BOEHRINGER INGELHEIM INT (DE) | 2011-08-17 | — | — | EP | claimed |
| EP-2311818-A1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | Novartis AG (CH) | 2011-04-20 | — | — | EP | claimed |
| EP-2269647-A2 | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-01-05 | — | — | EP | claimed |
| EP-2269648-A2 | Pharmaceutical compositions based on anticholinergically effective compounds and beta-mimetics | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-01-05 | — | — | EP | claimed |
| US-20100272638-A1 | RADIOLABELLED MICROPARTICLES, PROCESSES FOR THE PREPARATION THEREOF AND THE USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-28 | — | — | US | claimed |
| US-20100197719-A1 | MEDICAMENT COMPOSITIONS CONTAINING ANTICHOLINERGICALLY-EFFECTIVE COMPOUNDS AND BETAMIMETICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2010-08-05 | — | — | US | claimed |
| EP-1408967-B1 | PHARMACEUTICAL COMPOSITIONS BASED ON Tiotropium, Ciclesonide AND a BETAMIMETIC AGENT FOR THE TREATMENT OF INFLAMMATORY AND/OR OBSTRUCTIVE RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-10-28 | — | — | EP | claimed |
| EP-1178832-A1 | NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND BETA-MIMETICS | Boehringer Ingelheim Pharma KG (DE) | 2002-02-13 | — | — | EP | claimed |
| WO-2001011933-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A PDE4 INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001012191-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND A GLUCOCORTICOID | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001012192-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A-(2-AMINOETHYL)-BENZOTHIAZOLONE AND DISODIUM CROMOGLYCATE OR NEDOCROMIL | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2001012167-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING A 7-(2-AMINOETHYL)-BENZOTHIAZOLONE AND AN ANTICHOLINERGIC MUSCARINIC ANTAGONIST | ASTRAZENECA UK LIMITED (GB) | 2001-02-22 | — | — | WO | claimed |
| WO-2000069468-A1 | NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND BETA-MIMETICS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-11-23 | — | — | WO | claimed |
| EP-0649418-B1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | ASTRA PHARMA PROD (GB) | 1998-10-28 | — | — | EP | claimed |
| US-5648370-A | 7-(2-aminoethyl) benzothiazolones | ASTRA PHARMACEUTICALS LIMITED (GB) | 1997-07-15 | — | — | US | claimed |
| EP-0649418-A1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | Astra Pharmaceuticals Limited (GB) | 1995-04-26 | — | — | EP | claimed |
| WO-1993024473-A1 | 7-(2-AMINOETHYL)-BENZOTHIAZOLONES | FISONS PLC (GB) | 1993-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197719-A1 | MEDICAMENT COMPOSITIONS CONTAINING ANTICHOLINERGICALLY-EFFECTIVE COMPOUNDS AND BETAMIMETICS | CHRNE, CHRND, CHRM3 | ADRB2 4/4885ADRB1 11/4885DRD2 350/4885 |
| US-20120010179-A1 | Methods of using a thiazole derivative | ADRB2, NR3C2, ADRA2A | ADRB2 1/4885ADRB1 4/4885DRD2 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.